BayWa's Restructuring Hangs by a Thread as Legal and Financial Deadlines Converge

BayWa uses Cefetra sale proceeds as a bargaining chip with banks, but faces a €4B debt target, legal probes, and a failed core asset sale, with a crucial standstill deadline this fall.

A €107 million cash injection from the sale of its Cefetra business unit is set to hit BayWa's accounts by the end of April. For the embattled German conglomerate, this payment is less a solution and more a bargaining chip, buying precious time in a high-stakes negotiation with its core cooperative banks. The funds, comprising a €45 million sale payment and roughly €62 million in repaid shareholder loans, are earmarked to reduce bank debt by over €600 million through deconsolidation. Yet this figure is a mere fraction of the €4 billion total debt reduction target mandated by the company's restructuring plan through 2028.

The true litmus test arrives this autumn. Lenders DZ Bank and HVB must agree to extend a standstill agreement until fall 2026. Should they refuse, the StaRUG restructuring plan finalized in May 2025 loses its legal foundation, potentially plunging the company into chaos. The pressure on these institutions is already tangible; Bavarian cooperative banks have already written down 60% of a major bond loan, absorbing a €132 million loss.

While management scrambles for asset sales, a separate legal front has opened. Law firm TILP is preparing lawsuits for shareholders who purchased BayWa stock between January 2022 and January 2026. The action follows a formal reprimand from German financial watchdog BaFin, which accused BayWa of omitting crucial details about a billion-euro loan and refinancing risks for a €500 million bond from its annual report. In a parallel development, Munich prosecutors are investigating former CEOs Klaus Josef Lutz and Marcus Pöllinger on suspicion of breach of trust and the deliberate misrepresentation of liquidity risks in the 2023 financial statements. All accused are presumed innocent.

The company's governance and reporting mechanisms are under intense strain. Supervisory board members Monika Hohlmeier and Michael Höllerer resigned in late March, with Monique Surges set to follow at the end of May. In a move underscoring heightened oversight, the board lowered the threshold for transactions requiring its approval from €200 million to €50 million. Furthermore, the audited group financial statements for 2025 are not expected until the fourth quarter of 2026 due to complex revaluations necessitated by a failed flagship asset sale.

That failure represents the core of BayWa's financial dilemma. The original restructuring cornerstone was the sale of a 51% stake in its renewable energy subsidiary, BayWa r.e., projected to raise up to €1.7 billion. The plan collapsed in early 2025 after the United States scrapped subsidies for renewable energy, destroying the achievable sale price. With this key pillar gone, completed transactions—including Cefetra—have secured only €1.3 billion of the required €4 billion debt reduction.

Attention now turns to the sale of BayWa's approximately 74% stake in New Zealand fruit producer T&G Global, a process managed by Goldman Sachs since March 2026. The subsidiary, which returned to profitability with a net income of $16 million on $1.3 billion revenue in 2024, could fetch around €300 million. However, the process is complicated by minority shareholder Joy Wing Mau Group from Hong Kong, which holds nearly 20% of T&G.

The company's auditor, PwC, is also facing scrutiny. The German audit oversight body, Apas, has initiated professional disciplinary proceedings against the firm. The allegation is that PwC issued an unqualified audit opinion for 2023 without highlighting existential risks to the company, a potential breach of commercial code obligations. BayWa has put its audit mandate out for tender, with PwC set to audit the group's books for the final time for the 2025 fiscal year.

Operationally, the path is one of deep cuts. BayWa plans to eliminate 1,300 jobs and permanently close 26 branches by 2027. It has withdrawn its financial forecast for 2026 and lowered its adjusted EBITDA target for 2027 to approximately €140 million.

BayWa's share price reflects the profound uncertainty. Despite a nearly 13% gain on a recent Friday to €14.50, the stock remains about 33% below its 52-week high and trades roughly 19% below its 200-day moving average, having lost over 18% since the start of the year. Until a bank agreement is secured and audited financials are delivered in late 2026, investor sentiment will remain tethered to the shifting stance of its creditor banks.